SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES (Details) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Apr. 30, 2026 |
Apr. 30, 2025 |
Apr. 30, 2026 |
Apr. 30, 2025 |
|
| Share-Based Payment Arrangement [Abstract] | ||||
| Research, development, and clinical trial expenses | $ 175,999 | $ 36,493 | $ 338,446 | $ 120,050 |
| General and administrative expenses | 256,208 | 188,322 | 674,303 | 656,829 |
| Total share-based compensation | $ 432,207 | $ 224,815 | $ 1,012,749 | $ 776,879 |